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A B S T R A C T   
Background: Bacterial native vertebral osteomyelitis (NVO) can present diagnostic and therapeutic challenges 
leading to high levels of morbidity and mortality. To inform strategies aimed at improving outcomes in these 
patients, data are needed on the current aetiology, diagnostic interventions, management and risk factors for 
treatment failure. 
Methods: This was a retrospective, multicentre, observational cohort study of adult patients with bacterial NVO 
across the UK between 1st January 2015 and 31st December 2016. Infectious Disease Society of America (IDSA) 
guideline standards were selected and used to audit practice relating to the management of these patients. 
Results: A total of 286 patients were included from 40 hospitals. An organism was identified in 61% of cases by 
blood culture or biopsy. Of these, 51% were due to Staphylococcus aureus and 12% were due to Gram-negative 
bacteria. When performed, biopsy obtained a microbiological diagnosis in 50% of cases. Nearly 10% of pa-
tients required admission to an Intensive Care Unit, 20% were re-admitted to hospital, 56% experienced com-
plications and 6% died within 90 days. Higher Charlson comorbidity index (CCI) was significantly associated 
with treatment failure at one month (p = 0.004). 
Conclusions: This study identified opportunities to improve UK practice in the investigation and management of 
bacterial NVO. The range of organisms isolated supports the use of diagnostic biopsy where blood cultures are 
non-diagnostic, to guide antimicrobial therapy and strive to avoid treatment failure or complications. This study 
shows a clear need for antibiotic guidelines to reflect the current aetiology of NVO and authors support the 
creation of a formal registry.   
Introduction 
Native vertebral osteomyelitis (NVO), synonymous with spondylo-
discitis, is an important cause of back pain. It is associated with hae-
matogenous seeding or contiguous spread from local infection, but 
excludes infected implanted metalwork (Nickerson and Sinha, 2016; 
Zimmerli, 2010; Gasbarrini et al., 2005). Causative agents include 
bacteria, fungi or mycobacteria (Corrah et al., 2011; Kehrer et al., 2014; 
Gupta et al., 20142014). The incidence (up to 9.8/100,000 per year 
(Kehrer et al., 2014) has increased over the last 2 decades, possibly 
reflecting an ageing population (Kehrer et al., 2014; Mylona et al., 2009; 
Akiyama et al., 2013; Loibl et al., 2014). 
The variability of presenting symptoms (Kehrer et al., 2014; Loibl 
et al., 2014; GÖk et al., 2014) and low specificity of inflammatory 
markers often leads to diagnostic delay (Jean et al., 2017; Marchionni 
et al., 2019) and higher morbidity from disseminated disease or 
neurological complications (Widdrington et al., 2018; McHenry et al., 
2002; Kim et al., 2019). To optimise patient care, the Infectious Diseases 
Society of America (IDSA) published guidance, in 2015, which suggest 
clinicians initiate early investigations to identify causative microor-
ganisms (Chong et al., 2018; Gregori et al., 2019; Gouliouris et al., 
2011), give prompt therapy (Gouliouris et al., 2011; Park et al., 2019; 
Rutges et al., 2016; Bernard et al., 2015) and close follow up, ensuring 
resolution of symptoms and normalisation of inflammatory markers 
(Gasbarrini et al., 2005; McHenry et al., 2002). 
In this multicentre observational study, we set out to describe the 
characteristics of UK patients with NVO and established current man-
agement measured against selected IDSA standards. These standards are 
listed in Table 1. Also, we sought to determine which clinical, micro-




This was a retrospective, multicentre observational cohort study. The 
study protocol development was supported by the National Infection 
Trainee Collaborative for Audit and Research (NITCAR), a UK-based 
network of clinicians training in infection specialties, and adheres to 
STROBE guidelines (von Elm et al., 2014). The NHS Research Authority 
approved this study as an audit. 
Setting 
Sites were recruited in 2017, through promotional events at national 
and regional infection conferences, via NITCAR members and through 
the National Student Association for Medical Research. All hospitals in 
the UK were eligible for inclusion. Data were collected between 1st June 
2017 and 31st March 2018. 
Participants 
The first eight adult patients aged ≥ 16 years with a diagnosis of NVO 
presenting to participating sites in the two year period between 1st 
January 2015 and 31st December 2016 were eligible for inclusion. This 
strategy was chosen as a feasible number for individual sites to recruit 
based on pilot data collection. Patients with implant-associated verte-
bral osteomyelitis and patients previously diagnosed with NVO were 
excluded. 
Definitions and variables 
NVO is defined as bone infection of the spine not associated with 
implanted metalwork. It is confirmed by characteristic changes on im-
aging and a clinically compatible presentation (which may include back 
pain or discomfort, fevers and malaise) usually accompanied by raised 
inflammatory markers (ESR, CRP) (Berbari et al., 2015). In this study, 
investigators included patients diagnosed with NVO by their treating 
physician and given a corresponding ICD code, using the International 
Statistical Classification of Diseases and Related Health Problems (ICD) 
medical classification list by the World Health Organization. 
Variables were selected for inclusion based on a literature review of 
known associations with NVO. Patient variables included demographic, 
clinical (including Charlson comorbidity index (CCI) (Charlson et al., 
1987), microbiological, biochemical and radiological variables. These 
can be seen in Table 2. Additional hospital-specific data were collected 
to determine: the type of hospital; relevant services available at the 
hospital; local guidelines for the management of NVO. 
The primary outcome measure was evidence of treatment failure, 
defined as fever and/or static or rising inflammatory markers and/or 
death within 28 days after commencing treatment. The presence of pain, 
although used in some definitions of treatment failure, was not included 
here as we considered that it often represents previous vertebral damage 
and not necessarily ongoing infection. 
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Secondary outcome measures included audit standards chosen from 
the IDSA guideline for the diagnosis and treatment of NVO in adults 
(Berbari et al., 2015), detailed in Table 1. Standards were chosen by the 
NITCAR organising committee members based on their applicability and 
relevance to UK practice. 
Data sources, collection and analysis 
Participating centres chose their preferred method of identifying 
patients with NVO from the following list: clinical patient lists such as 
Outpatient Parenteral Antibiotic Therapy (OPAT) databases, infection 
team databases; radiology databases or ICD-10 discharge diagnosis 
codes/procedure codes. Details can be found in Supplementary mate-
rials: Table 1. Individual patients’ hospital records were examined by 
investigators to confirm a case of NVO prior to inclusion. 
Investigators at each site underwent webinar training, completed 
case report forms, entered anonymised data into a standardised 
spreadsheet (Microsoft Excel, 2007) and submitted this securely ac-
cording to Information Governance protocols. A copy of the case report 
form is provided in Supplementary materials: Appendix A. 
Statistical analysis 
Summary and descriptive statistics were reported for demographic 
details, clinical presentation, outcome and microbiological diagnoses of 
all patients in the study and for the selected audit standards. Patients 
with NVO secondary to tuberculosis, brucellosis and fungal infections 
were excluded from detailed analysis regarding management or 
outcome, due to different approaches taken in their care, making com-
parison to those with pyogenic bacterial infection inappropriate. Uni-
variable logistic regression models were used to estimate odds ratios and 
Table 1 
Audit standards used in this study, based on the 2015 Infectious Diseases Society 
of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment 






Details of IDSA guideline 
recommendation 
1 7 It is recommended that all patients 
with suspected native vertebral 
osteomyelitis (NVO) have a baseline 
CRP and/or ESR measured, and two 
sets of blood cultures taken at 
baseline* 
2 8, 9 It is recommended that all patients 
with suspected NVO undergo MRI 
spine. If this is not possible it is 
suggested that patients undergo spine 
gallium/Tc99 bone scan or computed 
tomography scan or a positron 
emission tomography 
3 14 It is recommended that all patients 
with suspected NVO undergo image- 
guided aspiration biopsy when a 
microbiologic diagnosis for a known 
associated organism (Staphylococcus 
aureus or Staphylococcus lugdunensis) 
has not been established by blood 
cultures or serologic tests 
4 21, 23 It is suggested that all patients with no 
microbiological diagnosis undergo a 
second aspiration biopsy or 
percutaneous endoscopic discectomy 
and drainage or open excisional 
biopsy if the first biopsy is non- 
diagnostic. This includes specimens 
with no growth or growth of a 
presumed skin contaminant such as 
coagulase-negative staphylococci, 
(except S. lugdunensis), 
Propionibacterium species, or 
diphtheroids 
5 26 It is recommended all patients have 
six weeks of parenteral or highly 
bioavailable oral antimicrobial 
therapy for bacterial NVO (with the 
exceptions of infection caused by 
Brucella or TB)^ 
6 32 It is suggested all patients have a 
clinical assessment and CRP and/or 
ESR monitoring approximately four 
weeks into treatment 
7 36 It is recommended all patients with 
suspected clinical treatment failure 
have a follow up MRI scan with 
emphasis on evolutionary changes in 
the paraspinal and epidural soft tissue 
findings 
8 37, 38 It is suggested that all patients with 
suspected clinical treatment failure in 
combination with suspected 
radiological treatment failure have 
further image guided aspiration 
biopsy or surgical sampling, and 
consultation with a neurosurgeon and 
Infection physician 
* For the purposes of this study, baseline investigations must have been taken 
within 96 h pre or post the time a diagnosis of NVO was suspected by the clinical 
team. 
^ For the purposes of this study, an antimicrobial regime was considered 
appropriate if it consisted of 6 weeks of parenteral antibiotics, or a minimum of 
2 weeks of parenteral antibiotics followed by a course which included oral 
ciprofloxacin to complete a minimum of 6 weeks of antimicrobial therapy. 
Table 2 
Demographic and clinical characteristics of individuals with NVO in this study.  
Characteristic Cases (n ¼
286) 
Gender - Female 99 (34.6%) 
Age (years) [median(IQR)] 64 (50–73) 
Ethnicity White 233 (81.5%) 
Asian/Asian British 20 (7.0%) 
Black/Black British 9 (3.2%) 
Other 7 (2.5%) 
Not documented 17 (5.9%) 
Charlson comorbidity index [median(IQR)] 1 (0–2) 
Immunosuppression/ 
Immunodeficiency 





Haemodialysis 2/27 (7.4%) 
Steroids 8/27 
(29.6%) 
Rheumatoid arthritis 7/27 
(25.9%) 
HIV 2/27 (7.4%) 
Other 4/27 
(14.8%) 
Other factors Recent trauma 11 (3.9%) 
Travel outside UK in the 
previous 12 months 
30 (10.5%) 
Intravenous drug use in 
previous 12 months 
27 (9.4%) 
Bacteraemia in preceding 12 months 54 (18.9%)  
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95% confidence intervals (CI) for any association between independent 
factors and treatment failure. Statistical analyses were carried out using 
Stata release 15 (StataCorp. 2017). 
Results 
Patient cohort and characteristics 
In total, 40 hospitals participated in the study. A full list of partici-
pating sites is available in Supplementary materials: List of participating 
sites. On-site infectious diseases services were available in 32 hospitals 
(80.0%), orthopaedics in 38 (95.0%), neurosurgery in 27 (67.5%) and 
outpatient parenteral antimicrobial therapy (OPAT) services in 35 hos-
pitals (87.5%). Site-specific guidelines for the management of NVO were 
available in 20 hospitals (50.0%), with 10 different empiric regimens 
reported, demonstrating a wide variety of antibiotic choices. This can be 
seen in Supplementary materials: Tables 2, 3 and 4. 
Demographic data for the 286 patients included in the audit is shown 
in Table 2. The majority were male (n = 187, 65.4%) and white (n =
233, 81.5%), with a median age of 64 years and relatively few comor-
bidities (median CCI 1). In the year prior to diagnosis intravenous drug 
use was reported in 27 patients (9.4%) and an episode of bacteraemia in 
54 patients (18.9%). 
Clinical features on presentation are summarised in Table 3. The 
majority of patients (n = 260, 94.2%) had back pain, while 43.2% had 
subjective fever and 33.5% had a neurological deficit. The median 
duration of symptoms, prior to presentation, was 17 days. An underlying 
source of infection was not identified in 46.9% of cases. There were no 
cases of NVO attributable to brucellosis or fungal infection and 11 pa-
tients were treated as tuberculosis (TB). 
A summary of microbiological findings is shown in Table 4. An or-
ganism was identified in 175/286 cases (61.2%). Of these, 90/175 
(51.4%) were Staphylococcus aureus; methicillin sensitivity data were 
collected for 68/90 (75.6%) isolates, all were reported as methicillin 
Table 3 
Presentation of patients with NVO in this study.    
Number (N ¼
286) 
Route of presentation ED/clinic 205 (71.7%) 
Transfer from another site 43 (15.0%) 
Ambulatory care 15 (5.2%) 
Other 13 (4.6%) 
Not documented 10 (3.5%) 
Symptoms on 
presentation 




Neurological deficit 84/251 
(33.5%) 
Delay from symptom onset to presentation (days, median (IQR) 17 (5–43) (n =
193) 




159 (n = 271)^ 
115 (51–253) 
Level of infection Cervical spine 43 (15.0%) 
Thoracic spine 104 (36.4%) 
Lumbo-sacral spine 170 (59.4%) 
No level documented 6 (2.1%) 
Radiological findings 
(on MRI) 
Osteomyelitis 277 (96.9%) 
Associated soft tissue infection (e.g. 
psoas abscess, sinus tract) 
64 (22.4%) 
Paravertebral extension of infection (e. 
g. paraspinal collection) 
86 (30.1%) 
Epidural extension of infection (e.g. 
epidural collection) 
77 (26.9%) 
Suspected source Skin and soft tissue infections 29 (10.1%) 
Genitourinary tract 22 (7.7%) 
Gastrointestinal sources 16 (5.6%) 
Endocarditis 16 (5.6%) 
Post-operative wounds 13 (4.6%) 
Respiratory tract 11 (3.9%) 
Tuberculosis 11 (3.9%) 
Endovascular infections 8 (2.8%) 
Dental infections 4 (1.4%) 
Intravenous catheter site 4 (1.4%) 
Other* 18 (6.3%) 
None identified 134 (46.9%) 
Denominators<286 reflect the number of patients where data were available. 
^Nb − 15/271 (5.5%) patients had a CRP < 10 mg/L at presentation. 
*Other – current or former IVDU (n = 5), discectomy (n = 5), Staphylococcus 
aureus bacteraemia (n = 2), septic arthritis (n = 2), ablation of renal cell car-
cinoma, bacterial meningitis, prosthetic joint infection, retropharyngeal abscess 
(all n = 1). 
Table 4 
Final microbiological diagnosis of patients with NVO in this study.  
Organism1  No. of cases 
(%) 
Gram positive Total number of patients 132 (46.2%) 
Staphylococcus aureus 90 (31.5%) 
Oral streptococci2 13 (4.5%) 
Enterococci3 6 (2.1%) 
Streptococcus dysgalactiae 6 (2.1%) 
Streptococcus agalactiae 5 (1.7%) 
Streptococcus pneumoniae 5 (1.7%) 




Other Gram positive 
organisms4 
3 (1.0%) 
Gram negative Total number of patients 33 (11.5%) 
E. coli 18 (6.3%) 
Pseudomonas species 3 (1.0%) 
Other Enterobacterales5 6 (2.1%) 
Other Gram negative 
organisms6 
7 (2.4%) 
Mycobacterium tuberculosis  11 (3.8%) 
Two organisms identified in same 
patient7  
5 (1.7%) 
No organism identified  111 (38.8%) 
All coagulase negative staphylococci (CoNS) (n = 15; 9 cases where CoNS was 
the only organism isolated on blood culture; 3 cases where CoNS were cultured 
alongside other, more pathogenic organisms from blood culture; 2 cases where 
CoNS was the only organism isolated from biopsy and did not grow on blood 
culture; 1 case where CoNS was cultured alongside other, more pathogenic or-
ganisms from biopsy). There were no isolates of Staphylococcus lugdunensis in this 
study. 
A Micrococcus spp. isolated from blood culture with Klebsiella spp. on biopsy. 
A Cutibacterium acnes which grew from one set of blood cultures, when a 
Staphylococcus aureus grew in the other set. 
A “Gram negative cocco-bacillus” from one set of blood cultures, which did not 
grow for further identification. 
1 Suspected contaminants excluded from the table above: 
2 Streptococcus gallolyticus (n = 4), Streptococcus gordonii (n = 2), Streptococcus 
oralis/mitis (n = 4), Streptococcus sanguinis (n = 2), not otherwise specified (n =
1). 
3 Enterococcus faecalis (n = 5), Enterococcus spp. (n = 1). 
4 Other Gram positive organisms – Atopobium parvulum, Cutibacterium (Pro-
pionibacterium) acnes (grown in both blood cultures and on biopsy) and Rothia 
mucilaginosa. 
5 Other Enterobacterales – Enterobacter cloacae, Klebsiella aerogenes, Klebsiella 
pneumoniae, Klebsiella spp., Proteus mirabilis and Serratia liquefaciens. 
6 Other Gram negative organisms – Acinetobacter baumannii, Aggregatibacter 
aphrophilus, Eikenella corrodens, Fusobacterium nucleatum, Neisseria mucosa/ 
macacae, Prevotella buccae and Salmonella enterica serovar Rissen. 
7 Cases where two organisms were identified in the same patient – S. aureus 
and E. faecalis isolated from biopsy; Streptococcus oralis/mitis isolated from bi-
opsy; Pseudomonas aeruginosa and Serratia liquefaciens both isolated from two 
sets of blood cultures; S. aureus and Streptococcus dysgalactiae isolated from one 
set of blood cultures; E. coli and Streptococcus intermedius isolated from one set of 
blood cultures. 
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sensitive (i.e. MSSA). Another pathogenic organism was identified in 
85/286 cases (29.7%). Gram negative organisms were identified in 33 
cases (11.5%). No significant organism was identified in 111/286 cases 
(38.8%). In three patients an organism was isolated from a distant site 
that was presumed to be the causative organism in NVO (Escherichia coli 
in urine culture and eye tissue and MSSA and Streptococcus pyogenes from 
a joint). Some cases had multiple organisms isolated. 
Patient management 
Full results of the audit against IDSA standards can be found in 
Supplementary materials: Full audit results. A minority of patients 
(7.6%) had a baseline CRP, ESR and two sets of blood cultures taken at 
baseline as recommended; however 77.8% had at least a baseline CRP 
and one set of blood cultures. All 286 patients in this study received 
appropriate imaging. 
The IDSA recommend that all patients with suspected NVO undergo 
biopsy unless S. aureus or S. lugdunensis are isolated in blood cultures. 
Fig. 1 illustrates the diagnostic pathway for this patient cohort and 
shows that 69/286 patients had S. aureus isolated in blood cultures at 
presentation (within 96 h.) The remaining 217/286 (75.9%) patients 
had negative blood cultures, or blood cultures that did not grow 
S. aureus or S. lugdunensis. Of these, 115/217 (53.0%) proceeded to bi-
opsy, which was diagnostic in 57/115 cases (49.6%). The most common 
reason given for not proceeding to biopsy was the isolation of alternate 
pathogens in blood cultures (e.g. oral streptococci or E. coli.) In patients 
with a non-diagnostic first biopsy, 10/58 (17.2%) proceeded to a second 
biopsy; 3/10 (30.0%) isolated an organism from this second biopsy. 
A minimum 6 week course of antimicrobial therapy was completed 
in 200/251 (79.7%) patients (excluding 11 patients with TB, 10 deaths, 
5 transfers to other hospitals, 1 lost to follow up and 8 with unknown 
outcomes). OPAT was utilised for 169/275 patients (61.5%). Between 
21 and 28 days of treatment, 89.9% patients received a clinical assess-
ment by a physician and 85.0% had CRP or ESR monitoring. There were 
14/40 hospitals with specific antimicrobial guidelines for the treatment 
of NVO: 7/14 used flucloxacillin as their first line agent. See Supple-
mentary Materials: Table S3 and Table S4. 
Patient outcome 
The outcome of 275 patients (excluding 11 TB cases) is summarised 
in Table 5. Nearly 10% (25/268) of patients required ICU admission and 
20.2% were re-admitted within 90 days. The majority of patients (145/ 
261, 55.5%) experienced complications. At one month, 9 patients 
(3.3%) had been lost to follow-up, 9 patients (3.3%) had died and an 
additional 36 patients (13.4%) met criteria for suspected treatment 
failure. 
Of the 36 patients with suspected treatment failure, at 21–28 days 
post-initiation of antibiotics, 35 (97.2%) were either referred or already 
under the care of a specialist team and 17 (47.2%) had repeat imaging. 
Fig. 1. Flow diagram of the diagnostic pathway for microbiology samples in the 288 NVO patients in this study.  
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This demonstrated radiological evidence of worsening infection in 5 
cases (3 showed worsening osteomyelitis/discitis, 1 showed worsening 
epidural extension, 1 showed worsening soft tissue infection). None of 
these patients had further biopsies. 
Risk factors for treatment failure 
The results of a univariable logistic regression analysis undertaken to 
assess potential risk factors for treatment failure is summarised in 
Table 6. A higher CCI was the only risk factor for treatment failure that 
was statistically significant with a p-value of < 0.05, increasing the odds 
of treatment failure by 1.24 (95% CI 1.07–1.42) for each additional unit 
of the CCI. 
Discussion 
To our knowledge this is the largest retrospective multicentre cohort 
study of UK patients with NVO. Practice deviated from IDSA recom-
mendations in several areas. There were low rates of diagnostic biopsy 
and few patients underwent repeat biopsy where the first had been non- 
diagnostic. This may stem from uncertainty in the approach to patients 
with bacteraemia with organisms other than S. aureus or S.lugdenensis. 
IDSA guidance suggests that pursuing a biopsy in this situation is left to 
clinical discretion and, in this study, clinicians were often sufficiently 
convinced that they had isolated the causative agent on blood culture 
that biopsy was not felt warranted. This approach is supported by our 
finding that lack of microbiological diagnosis was not found to be a 
significant contributor to treatment failure. 
There was a concerning minority of patients (6/102) who did not 
undergo a biopsy due to lack of access to this procedure. Anecdotally, a 
lack of robust referral pathways for centres without on-site surgeons or 
interventional radiologists may account for this. As only 10% of the 
included patients were from non-teaching hospitals, our study may 
underestimate this issue. 
The management of suspected treatment failure also differed from 
IDSA guidelines, with few patients undergoing repeat imaging or biopsy. 
This may reflect variability in the definition of treatment failure used in 
practice. The time period of follow up (21–28 days) was chosen as it 
aligned to the follow up recommended by the IDSA guidelines and was 
judged useful clinically. Although 21% of patients with repeat imaging 
had worsening appearances, only a quarter of these met our definitions 
for clinical failure. This illustrates a distinction between clinical and 
imaging findings and the complexities in identifying patients who have 
truly failed therapy. 
CCI was the only factor independently associated with clinical 
treatment failure. Due to the small size of the treatment failure group, 
other smaller effects may have been missed. Comorbidities are 
commonly associated with NVO and are associated with poor outcome 
(Mylona et al., 2009; Akiyama et al., 2013; Widdrington et al., 2018). 
The only other variable approaching statistical significance was the 
borderline protective effect of an epidural abscess identified on baseline 
imaging. However, previous studies have identified this as a risk factor 
for treatment failure (Skaf et al., 2010; D’Agostino et al., 2010). 
The patient characteristics and microbiology in this cohort reflect 
previous studies (Zimmerli, 2010; Gasbarrini et al., 2005; Kehrer et al., 
2014; Mylona et al., 2009; Gouliouris et al., 2011). Diagnostic delay in 
NVO is often several months (Gasbarrini et al., 2005; GÖk et al., 2014); 
the shorter time identified here may reflect lower incidence of TB and 
brucellosis in the UK or easier access to imaging (Jean et al., 2017). 
Monomicrobial infection with S. aureus or streptococcal species was 
most common with a smaller but significant number of Gram negative 
infections. Previous cohorts have reported S. aureus as a causative or-
ganism in 32–67% cases (Nickerson and Sinha, 2016; Mylona et al., 
2009) and ours reported 31.5%. No MRSA was detected, reflecting 
current low rates of MRSA carriage and invasive disease in the UK in 
comparison to the US (Dudareva et al., 2019). We acknowledge methi-
cillin sensitivity data were limited (in 68/90 isolates) as the initial data 
collection did not capture this information and sites were asked to 
conduct a secondary data collection where possible. These findings 
highlight the need for national guidelines to support best prescribing 
practice. 
A microbiological diagnosis was obtained in 61.2% of patients. This 
is lower than previously reported (Gupta et al., 20142014; Mylona et al., 
2009) and may be partly explained by low biopsy rates. Biopsy or 
aspiration yielded a microbiological diagnosis in 49.6%, but a micro-
biological diagnosis was not obtained in 38.8% patients. As lack of 
microbiological confirmation has previously been associated with a 
higher likelihood of attributable readmission and death (Chong et al., 
2018), this is a key area for improvement. 
The key strength of this study is the large number and variety of 
patients included from multiple sites over a comparably short timeframe 
(Corrah et al., 2011; McHenry et al., 2002) made possible using a na-
tional multicentre collaborative and novel recruitment strategies 
through trainee and student networks. The results should be applicable 
to most sites within the UK and are likely to be generalisable to other 
centres in high income settings with similar rates of TB and antimicro-
bial resistance. However, the retrospective design brings risk of bias. 
Sites chose their method of case ascertainment, so there may be het-
erogeneity between cases submitted by different sites. Also sites were 
asked to recruit the first 8 patients presenting to their trust over a 2 year 
period. This strategy was chosen as a feasible number for individual sites 
to recruit based on pilot data collection and to avoid overrepresentation 
of tertiary centres. We acknowledge that this may have introduced 
sampling bias. 
To study larger prospective cohorts of those with NVO would require 
greater collaborative networks, such as the recently developed European 
Endocarditis registry (Habib et al., 2019), a comparable infectious dis-
ease in terms of its relatively low incidence, high morbidity and multi-
disciplinary management. In conclusion, this retrospective study has 
explored the differing management and outcomes of UK patients with 
NVO and shown that causative organisms vary in prevalence compared 
to the US, confirming the urgent need for guidelines reflecting local 
epidemiology and best practice. 
Table 5 
Outcome of patients with NVO in this study, excluding cases of tuberculosis (N 
= 275).  
Outcome  Number (N ¼
275) 
Patient Care Inpatient only 103 (37.5%) 
OPAT only 15 (5.5%) 
Both inpatient and OPAT 154 (56.0%) 
Unspecified 3 (1.1%) 
ICU Admission  25/268 (9.3%) 
Symptoms at 90 days Pain 115/186 (61.8%) 
Neurological symptoms 32/186 (17.2%) 
Readmission within 90 days All cause 49/243 (20.2%) 
Due to NVO 30/243 (12.3%) 
Complications Any 145/261 (55.5%) 
Spinal abscess 97/261 (37.2%) 
Distant abscess 21/261 (8.0%) 
Stroke 5/261 (1.9%) 
Endocarditis 18/261 (6.9%) 
Surgical drainage of 
abscess 
24/261 (9.2%) 
Surgical fixation 16/261 (6.1%) 
Death at 90 days 16/271 (5.9%) 
Treatment failure at one 
month 
Clinical failure* 36/269 (13.4%) 
Death 9/269 (3.4%) 
Combined 45/269 (16.7%) 
*Clinical treatment failure defined as persistent fever and/or rising inflamma-
tory markers 21–28 days after commencing treatment. 
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Table 6 
Risk factors for treatment failure at 28 days of treatment (N = 269*).  
Variable Category No treatment failure (n ¼
224) 
Treatment failure (n ¼
45) 







30  1.08 
(0.55–2.15)  
0.80 































5  1.21 
(0.43–3.39)  
0.72 





8  0.84 
(0.36–1.92)  
0.67 





17  0.92 
(0.46–1.83)  
0.82 





39  0.36 
(0.18–1.87)  
0.21 





12  0.79 
(0.38–1.64)  
0.52 
CRP (mg/L), median (IQR)  112 (53–259) 157 (97.5–277) 1.00 
(1.00–1.00) 
0.39 





67 13 0.95 
(0.47–1.93) 
0.89 
Epidural collection 66 7 0.43 
(0.18–1.02) 
0.054 
Organism Staphylococcus aureus 73 16 1.14 
(0.58–2.23) 
0.70 
None identified 90 15 0.74 
(0.38–1.46) 
0.39 













25  1.25 
(0.65–2.43)  
0.50 
Time from symptom onset to first dose of antibiotics (days), 
median (IQR) (n)  
22.5 (7–63.5) (n = 152) 14 (4–42) (n = 22) 0.99 
(0.98–1.00) 
0.26 
*Exclusions: 11 patients with TB; 5 patients who were transferred to a different care setting prior to 28 days of treatment; 1 patient lost to follow up. 
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